Patent · US Active

Injectable flowable composition comprising buprenorphine

US8975270B2 · kind B2 · utility

19Cited by

0References

15Claims

0Family size

Assignee

RB PHARMACEUTICALS LIMITED · GB

Inventors

Richard L. Norton · Fort Collins, US
Andrew Watkins · Richmond, US
Mingxing Zhou · Fort Collins, US

Key dates

Filing date	Mar 15, 2013
Grant date	Mar 10, 2015
Priority date	—
Expiry date	Jun 14, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K47/34
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.